STOCKS TELEGRAPH

Author: ST Staff

Inuvo Inc (INUV) stock surged in the current trading session; find out why

In the current trading session, Inuvo Inc. (INUV) stock has surged by 14.81% to $0.88 at the time of writing. INUV stock previously closed the session at $0.77. The INUV stock volume traded today at 2.75 million shares, while the average 3 months volume traded at 7.57 million. In the last 5 consecutive trading sessions, the INUV stock has jumped by 4.72%. In the past year, INUV shares soared by 242.49%. Furthermore, Inuvo Inc. is currently valued in the market at $89.75 million and has 97.94 million outstanding shares.

Inuvo Inc.’s background operations

Inuvo Inc. is a technology company that specifically focuses on information technology solutions and services business model. The company develops and sells information technology solutions; its product offering includes identifying the customers who are basically online audiences and messaging them regarding various products and sales pitch. This is done across many channels and formats that include mobile, connected TV, social media.

Use of AI technology for digital and modern marketing

The Inuvo’s platform allows advertisers and publishers to purchase advertising space in real time. Valiclick is the company’s marketing services which are provided either online or indirectly to various advertisers. This marketing service combines data analytics, digital marketing, and software to direct the tailored audience and platform for the merchant advertising messages with consumers (anonymous identity).

Inuvo has also dwelled into the artificial intelligence segment to enhance its marketing services. IntentKey is an artificial intelligence system that recognizes the consumers’ intent and behavior pattern when visiting and surfing through the internet and specifically websites.

Saracen Casino Resort utilizes IntentKey across all media channels

On 22^nd April 2021, Inuvo inc. made a press release that describes how their proprietary Artificial intelligence System- IntentKey has helped with the marketing strategy and provided artificial intelligence-based data and analytics to give insight into the behaviors of the audience for the Saracen Casino Resort.

Saracen Casino Resort is Arkansas’ only purpose-built casino. The agency of record for the largest and most sophisticated casino is Heathcott Associates that aimed to use the most highly advanced and latest cutting edge marketing tactics for the Casino Resort. This is where Inuvo Inc. entered the picture with its AI-generated insights; the aim was to somehow generate month-over-month revenue growth even in pandemic and for that, they needed highly specialized and tailored marketing leads.

The IntentKey adjusts and collects real-time data based on how consumers change their behaviors on websites and the internet. It then tailors that data and incorporates it into its insights which helps the marketing team initiate a strategy for marketing and attract an audience.

IntentKey is Inuvo Inc.’s superior and cutting edge marketing solution

Saracen Casino Resort saw the potential of IntentKey and implemented a budget in which the AI marketing system was incorporated with every media channel and platform. The AI platform has proved itself to be a cutting-edge marketing tool in the digital marketing era that stands out and attracts a lot of heavy clients and huge projects – which translate to great revenue margins the Inuvo Inc. and attractive information technology stock for people to invest in.

April 26, 2021
Casper Sleep Inc (CSPR) stock surged in the current trading session; here’s why

At last check, Casper Sleep Inc. (CSPR) stock surged by 26.14% to $8.88 in the current trading session. CSPR stock previously closed at $7.04. The stock volume traded today is 10.96 million shares. 3 months average volume of stock trade is 696.52k. In the past year, CSPR stock jumped by 11.75%. In the last three and six months, the stock plunged -7.85% and -6.88% respectively.

Analyst updates rating on CSPR stock

Today Casper Sleep Inc. also surged as trading got underway in the first hour of the session. This was due to external news related to analyst rating. Wedbush analyst made an upgrade from a “neutral” rating to an “outperform rating” with the target price adjusted to $10.50 from $10.0. This positive analyst rating always attracts good news and confidence from the investors which had caused a jump of 28% in the first half-hour of trading.

CSPR Stock’s product offering

Casper Sleep Inc. was formerly a mattress company known as Providence Mattress Company that produced mattresses however it changed the name in January 2014. Afterwards, Casper Sleep produced, designed and sold a variety of sleep centric products and services. These product offerings include sleep related products like mattresses, pillow, bed sheets, sleep accessories and gadgets, along with other services.

The company has an award winning R&D team at Casper Labs that designs the sleep-centric products. It has an online retail platform now and operates 67 retail stores along with 20 retail partners.

Introducing new line of innovative Casper Cooling Collection

Analyst rating isn’t the only thing that had improved about CSPR stock; the company’s basis of operations expanded to a new innovative product line which attractive features. On 20^th April, Casper Sleep Inc. (NYSE: CSPR) announced a new line of innovative sleep products known as Casper Cooling Collection. This innovative line of products are specialized to give cooling effects which was done thanks to R&D’s efforts on utilizing the most advance technological solutions to optimize the cooling effect during sleep.

Research Development team came out with a research study that concluded that the most important variable that affects the sleep quality during the night is temperature. The study showed 64% of the people surveyed had reported that the most common temperature problem while sleeping is the irregularity and irritability of sweating and overheating.

What does this new product mean for the company?

What the company essentially is figure out another niche in the sleep-related products and met the niche demand using their innovative and creative technological resources to bring about the solution- Casper Cooling Collection. The new line of products contains the company’s proprietary Snow Technology.

Furthermore, the whole suite of the collection includes Hyperlite Sheets, Lightweight Duvets, Breathable Mattress Protector. The Snow Technology mattresses consist of two main mattresses known as Casper Nova Hybrid Snow Mattress and Casper Wave Hybrid Snow Mattress which have the innovative feature of pulling away the heat from your body on the mattress.

Overall the mattress combines four unique features to generate as much comfort through cooling and has undergone 150 lab tests by the Casper R&D team which showed sustained temperature regulations.

April 26, 2021
MICT stock has surged in the premarket trading session; let’s find out why

In the premarket trading session, MICT stock has surged by 16.97% to $1.93, at the time of writing. MICT stock closed the previous session at $1.65. Stock volume traded today was 1.35 million shares. The average trade volume for the past 3 months is 7.89M. In the past year, MICT has stock surged by 50.96%.In the past 5 days, the shares jumped by 3.12%. In the last three months, the stock has lost -27.95%. MICTis currently valued at $185.00 million and has 65.35 million outstanding shares.

MICT’s basis of operations

MICT Inc. runs its course of operations through its two subsidiaries Micronet Ltd. and Global Fintech Holdings Intermediate Ltd. The subsidiaries provide two basis of operations; proprietary trading technology platform and computing solutions.

Global Fintech Holdings Intermediate Ltd. focuses on clients for high-growth sectors in the global Fintech industry. The trading technology platform includes services and solutions like online brokerage for equities trading, investments through digital platforms, wealth management services, and insurance products based sales services, and certain commodities based trading. The company targets high-growth foreign markets which includes the Asian market where GFHI has collaborated with commercial partners, online portals and has a database of a network of users that is proprietary.

Micronet focuses on designing, developing, and selling mobile computing solutions. Micronet targets clients in the telematics and commercial Mobile Resource Management market. The main regions where it deploys its resources and operations are in the United States and Europe.

Robert Benton; newest member addition in BOD

On 16^th April 2021, MICT announced the addition of a new member by the name of Robert Benton to the MICT’s Board of Directors. The company’s current board member John Scott has been assigned a new role of non-executive deputy chairman of the company’s Board of Directors.

Robert Benton is a seasoned financial executive with experience from various previous roles such as being the Chairman of the Board in a Financial Times Stock Exchange 250 company named Clarksons. Robert Benton has assumed the position of Jeff Bialos who left the position of Board of Directors effectively on 12^th April 2021.

John Scott has been working for MICT for the past 18 months and has spent the last 50 years gaining experience from numerous brokerage firms. Previously, John Scott worked in the roles of senior management designations for investment banks which include the leading Canaccord Adams, HSBC James Capel, and ABN AMRO.

How MICT is preparing to solidify its fundamentals

The company has majorly shifted its strategy from a telematics business model towards fintech in China and Southeast Asia market. The company did suffer an overall loss in the previous year but part of which occurred for acquisitions and strategy shift that have become investments that rewards of which are/will be reaped in the current year 2021 and future years to come.

Furthermore, MICT is excited about the potential of 3 of its new portfolios; proprietary stock trading platform, commodities, and futures trading platform as well as the new three fintech verticals. Each portfolio individually has strong growth prospects.

Shareholders and investors in MICT will possibly see benefits of long-term investments in the MICT stock as the company has shifted from transitional phase to growth phase in its operations; promises of foreseeable revenue growth.

April 26, 2021
AgeX Therapeutics, Inc. (AGE) stock rises over 10% Pre-Market today: Why is it so?

Shares of the AgeX Therapeutics, Inc. (AGE) stock were rising in the pre-market trading session on Monday, April 26, 2021. AGE stock price saw a surge of 11.97% to reach $1.59 a share as of this writing. AgeX Therapeutics was gaining in the previous trading session and went up by 1.43% having a $1.42 per share price at closing. Let’s try to find the reason behind this bull.

What’s Happening?

Sometimes nothing is good for everything and the same is the situation for AgeX Therapeutics as we find no recent news by the AgeX Therapeutics, not even in whole April, no analysts upgrades, or upswing targeted per share price of AGE stock to justify the rally. Furthermore, no sympathy play or social media hype is supporting this rally. So, what you need to know at this point? Here is the previous activity by the AgeX stock.

Fourth-quarter and full-year 2020 financial results:

AgeX stock did release its fourth quarter and year 2020 financial results on March 31, 2020, according to which the fourth-year revenue of the AGE stock was recorded $0.5 million while the total revenue of the full year 2020 was $1.9 million as compared to $1.7 million of 2019. Operating expenses for the last three months of 2020 were totaled $2.9 million while these were $12.4 million, higher than the $10.4 million in 2019.R&D expenses reduced to $5.0 million in 2020 as compared to $5.9 million in 2019. General and Administrative expenses for the AGE stock were decreased to $7.4 million in 2020 from $8.1 million in 2019.

At the end of 2020, AGE stock had cash, cash equivalents, and restricted cash of $0.6 million as compared to $2.5 at the end of the prior year. Loans from Juvenescence, disposition LifeMap Sciences, Inc, a subsidiary of AgeX, and offering of shares of AgeX common stock resulted in net proceeds of $3.2 million as of January 1, 2021.

Conclusion:

Though the AGE stock is hot among investors so far, we don’t find any specific news related to it to justify the bullish sentiment. AgeX recent financial results show that the AGE stock has shown growth over time but still, deep analysis of its balance sheet, fundamentals, and future growth is necessary before adding this stock to the portfolio.

April 26, 2021
Riot Blockchain, Inc. (RIOT) stock rises in the Pre-market today: Why is it so?

Shares of the Riot Blockchain, Inc. (RIOT) were rising in the pre-market trading session today on April 26, 2021, after rising as much as 5.45% at closing. RIOT price saw a surge of 8.11% to reach $41.6 a share as of this writing. It seems that the RIOT stock is moving high without any particular reason. Let’s deep dive to explore more of it.

What’s happening?

There is no specific news or earnings report by the RIOT to explain the reason behind the rally. We find no signs of analyst upgrades or increased per-share price of the RIOT to justify the rising RIOT Stock price. This is spreading curiosity among individuals eying on Riot Blockchain. Now it is better to analyze some of the past activities of RIOT stock.

Recent Developments:

On April 08, 2021. Riot stock entered into the definitive agreement with Whinstone US, Inc (“Whinstone”), pursuant to which Whinstone along with all its assets and operation will be acquired by the RIOT. The transaction value for this deal totaled approximately $651 million based on the per-share price of $48.37 of RIOT stock at that time.

On April 06, 2021, RIOT stock did announce the appointments of Megan Brooks, Phil McPherson, and Ryan Werner for the positions of Chief Operating Officer, Vice President, Capital Markets, and Vice President, Finance respectively in order to support the substantial progress which RIOT is making as a result of its strategic initiatives.

RIOT stock production in March 2021:

On April 12, 2021, RIOT stock did announce the March production and its operation updates according to which Riot Blockchain produced 187 BTC, which represents an increase of 80% as compared to 104 BTC in March 2020.BTC production in the first quarter of 2021 rose by 75% to reach 491 BTC as compared to the production of 281 BTC in the first quarter of 2020.

Conclusion:

Things are going well for RIOT stock as far as market sentiment is concerned without any recent news related to it. The previous developments show that the Riot Blockchain is growing over time. In a nutshell, investors need to keep an eye on this stock.

April 26, 2021
Why Inovio Pharmaceuticals, Inc. (INO) stock is rising in the Pre-Market today?

Shares of Inovio Pharmaceuticals, Inc. (INO) stock were rising in the pre-market trading session today after dropping as much as 30% during the last trading session. INO price saw a push of 0.58% to reach $6.89 a share at the time of this writing. INO dropped by 24.97% at the previous closing with a $6.85 per share price. Let’s see the reason behind this bull.

What’s happening?

Today’s bullish sentiment has nothing to do with any good news related to INO stock. There are no signs of analyst upgrades or increased targeted per share price of the INO to justify the rising behavior of INO stock. However, INO stock faced a massive drop of 30% during the last trading session after the announcement on Friday, April 23, 2021, that it’s funding for late-stage study testing of COVID-19 vaccine candidate has been stopped by the U.S government due to the excessive availability of authorized vaccine in the country. However, funding for the ongoing mid-stage study testing will continue for the vaccine candidate of INO by the U.S government.

The stopping of the fund for the late-stage study testing of a COVID-19 vaccine candidate resulted from the changing environment of COVID-19 amid the rapid development of vaccines and does not reflect the awardee or product. Moreover, this decision is also not a reflection of any data released for the INO-4800 vaccine. INO stock will continue to perform other operations with the U.S. government without any effect.

Inovio is planning for a late-stage global study with its global collaborators INOVIO’s China partner, Advaccine, and the International Vaccine Institute (IVI,) based on the upcoming results related to safety and immunogenicity from mid-stage trial.

Inovio Pharmaceuticals, Inc:

Inovio Pharmaceuticals, Inc is a biotechnology company focused on the treatment of human papillomavirus (HPV) related diseases via the development of DNA medicines. INO stock has also been working on the development and commercialization of medicines to treat cancer and various infectious diseases. INO stock having a market cap of 1.908B was founded in 1979 and its headquarters is in Plymouth Meeting, Pennsylvania.

Conclusion:

The INO stock price is rising in the stock market today despite the absence of any good news related to it.INO stock experienced a massive drop in the previous trading session. Sometimes investors take it as the opportunity to purchase shares of a particular stock at a lower price considering the long-term benefits. In short deep fundamental and technical analysis is necessary before adding INO stock to the portfolio.

April 26, 2021
Ocugen Inc. (OCGN) stock has surged in the premarket trading session. Here’s why

In the premarket trading session, Ocugen Inc. (OCGN) stock soared by 20.56% to trade at $11.61at the time of writing. OCGN closed Friday’s session at $9.63 with a 3.66% gain. The OCGN stock volume traded 504.64 million shares today. The average volume of trade for the past 3 months has been 69.44 million. In the past year up to date period, OCGN stock surged by 2891.61% while rallying by 66.61% for the past 5 consecutive days. In the last three months, OCGN shares added 341.74%, and further added 2957.14%. In the last six months. Ocugen Inc. is currently valued in the market at $1.75 billion and has 188.09 million outstanding shares.

Ocugen’s retinal therapy product offering

Ocugen Inc. is a biopharmaceutical company that is focused on designing, developing, and commercializing of innovative therapies that aim to target the unmet needs of patients with diseases. The transformative therapies that the company designs are gene therapies that specifically developed for targeting blindness diseases and restoration of sight. Ocugen Inc. uses proprietary modifier gene therapy platform which has become a breakthrough in treating multiple retinal diseases with one drug. Furthermore, OCGN stock has novel therapies for the treatment of age-related macular degeneration (AMD), diabetic retinopathy, and diabetic macular edema.

Announcing a definitive agreement for a $100 million direct offering

On 24^th April 2021, Ocugen Inc. announced that it entered into an agreement with healthcare-focused institutional investors. This definitive agreement was made for the sale of $100 million registered shares of OCGN’s common stock in a direct offering at a price per share of $10. The deal is expected to take place around 27^th April 2021, if everything happens according to customary closing conditions and satisfaction.

These healthcare-focused institutional investors’ offering were placed through the exclusive placement agent firm known as H.C. Wainwright & Co. The purpose of the offering and the deal is for OCGN stock to use the net proceed for general business activity and corporate purposes.

Bharat Biotech achieves positive second interim data for its COVAXIN, COVID-19 vaccine study

On 22^nd April 2021, announced that Bharat Biotech (co-development partner) has achieved success in a late-stage study of COVAXIN. COVAXIN is a vaccine in development for COVID-19 and the positive data of the study made the shares of the OCGN stock go up the charts.

The study of COVAXIN was in its phase III and the second interim analysis demonstrated a positive result of 78% efficacy for COVID-19 in mild, moderate-severe COVID-19 symptoms and variants while the study also claims that in the severe cases of COVID-19, COVAXIN showed 100% efficacy. The study also had a subgroup of participants for the RT-PCR test and found that the efficacy against asymptomatic COVID-19 infection was 70%.

OCGN stock’s future plans of commercializing

The company has planned an agreement its co-development partner Bharat Biotech to distribute and commercialize COVAXIN in the U.S market which includes the technology transfer of manufacturing and share in the profits of US market sales- Ocugen will retain 45% of the profit. Furthermore, Bharat Biotech is waiting for the Emergency Use Authorization which will allow it to supply a certain amount of minimum number of COVAXIN doses.

April 26, 2021
InspireMD Inc. (NSPR) stock soared in the after-market trading session; let’s find out why

In the after-market trading session, InspireMD Inc. (NSPR) stock had soared by 12.54% to trade at the price of $0.5214at the time of writing. In Friday’s trading session, NSPR stock closed with a gain of 2.96% at the price of $0.46. The stock volume traded at 4.71 million shares. The average trading volume for the past months has been 15.24 million, showing a decline in today’s stock volume. NSPR stock had declined by -36.55%for the year up to date. In the past 5 consecutive trading sessions, the NSPR shares had jumped by 13.00%. In the past three and six months, the NSPR stock slumped by -33.68% and jumped by 21.60% respectively. InspireMDInc is currently valued in the market at $53.03 million and has current outstanding shares at a total of 117.79 million.

The operational background on InspireMD

InspireMD Inc. is a medical device company that specifically focuses on the production and provision of the stent and stent-related products. The company aims to design their own proprietary MicroNet stent platforms technology solutions. These are used to create innovative applications for the treatment of vascular, coronary diseases, carotid artery applications specifically for acute coronary syndromes, saphenous vein graft coronary blockages and serious myocardial infarction.

InspireMD claims to have the most advanced Carotid Stenting system in the market

InpsireMD has created product offerings of preventive systems including the CGuard carotid embolic prevention system, MGuard Prime embolic protection system, and also developing of NGuard. NGuard is created for the purpose of diverting the blood flow to seal the aneurysms by diverting blood flow away from cerebral aneurysms.

InspireMD’s diverse range of product offering based on the proprietary MicroNet embolic protection and stenting platform have allowed it to enter the market boldly as a top-line provider of superior technology carotid stent systems in the market.

InspireMD updates its recent corporate activities

On 19^th April 2021, InspireMD provided an update about its recent developments in operations and business activities; a 1:15 reverse stock split will take place today (26^th April 2021) as the trade closes which will reduce the number of outstanding shares directly from 118 million to 7.9 million shares. On April 27^th the NSPR common stock will trade on an adjusted split basis on the platform of NYSE American. Total number of common stock will remain at 150 million.

A submission had been made on the same day by NSPR stock to be enlisted in the Nasdaq Capital Market. This move helps to expand the listing for NSPR stock and makes it more attractive to a wide range of customers.

The company had previously raised capital of an estimated $20.7 million. This capital raise will help InspireMD to progress and execute its C-Guardian FDA clinical trial, maintainCGuard EPS as the top available carotid stent system in the market, and to sustain their growth of operations and product innovation goals.

April 26, 2021
Why Birks Group Inc. (BGI) stock rallied in the Friday aftermarket?

Shares of Birks Group Inc. (BGI) stock were rising in Friday’s aftermarket session after soaring as much as 27.55% with a $2.5 per share price at previous closing. BGI stock price saw a push of 12% to reach $2.8 a share in the late hours of yesterday on April 23, 2021. What made this penny stock high? Let’s try to understand the reason behind this.

What’s happening?

Birks Group Inc is the designer, developer, manufacturer, and retailer of Jewelry and gift accessories in the United States and Canada. This rising BGI stock price has nothing to do with any particular activity by the Birks Group. There is no recent specific news, not even in the whole April, or earnings report, no analysts upgrade or shrank targeted per share price of the BGI stock to justify this rally. Sometimes social media hype makes the stock outperform but this rally is not justifying this fact. This is something confusing for investors who are eagerly looking for some reason behind this rally to calm themselves. So what you need to know now at this point? Here is the previous news of BGI stock.

FY2021 Holiday Period Sales Results

On January 14, 2021, Birks stock did announce the interim holiday sales result of the period November 1, 2020, through December 26, 2020. According to the report, net sales represented a reduction of 0.2% as compared to last year as stores were temporarily closed in some regions of Canada due to the Coronavirus outbreak. 7 out of 29 retail stores of the Birks stock were temporarily closed for in-person shopping due to health restrictions. The comparable sales after excluding the 7 stores were increased by 6.8%.E-Commerce sales represented huge growth of 176.0% during the FY2021 Holiday Period.

The CEO and president of the Birks Group was satisfied with the sales result of the holiday period and appreciated the whole management for its efforts in delivering good holiday results, especially in the eCommerce business despite the adverse effects of COVID-19.

Conclusion:

BGI stock captivated the attention of investors due to its continued rising trend despite no specific activity by Birks Group. Birks Group is following the sales trends and that’s why it showed great results in eCommerce sales. In a nutshell, BGI stock is performing well so far but the in-depth analysis is necessary before adding this stock to the portfolio.

April 24, 2021
UP Fintech Holding Limited (TIGR) stock surged in the current trading session; find out why

In the current trading session, UP Fintech Holding Limited (TIGR) stock surged by 10.75% to the price of $20.30 at the time of writing. TIGR stock previously closed the session at $18.33. The TIGR stock volume traded today about 5.96 million shares. While the average day trading volume for the past 3 months has been 10.10 million. This shows that the number of hands exchanged in today’s trading session were less compared to the average.

In the past year, TIGR stock has surged by 534.26%. However, in the past week, the stock dropped by-3.12%. In the past three and six months, the shares have has lost -0.43%, while gaining 288.35% respectively. Furthermore, UP Fintech Holding Limited (TIGR) currently has a market value of $2.56 billion and has 141.33 million outstanding shares.

Tiger Brokers have transformed retail brokerage to online brokerage

Tiger Brokers is a leading online brokerage firm that specifically focuses on the serving of global investors with stock trading brokerage services. It operates its services in major markets of the US, Hong Kong, UK, and other markets. The company has shifted to online platform from retail brokerage firm, in order to innovatively approach the brokerage business through the new era of digitization and ease of access at the touch of your phone. The online brokerage now covers not only brokerage but also ESOP, wealth management and investment banking.

TIGR stock worked together with Aurora Mobile to expand its online brokerage capabilities while strengthening the TIGR APP’s core and functions. Aurora Mobile is China’s leading mobile developer service provider and suits to be the partner for TIGR since it focuses on adapting to the needs of the developers and has provided 1.65 million APPs with software development kits (SDK). Aurora Mobile will utilize its Artificial Intelligence based technology and developer expertise to TIGR’s vision of providing smooth and enhanced push notification services and deep-learning based analytical capabilities and data processing.

For the year 2020, TIGR had its revenue doubled for 3 consecutive quarters which made it the fastest growing stock broker in the United States and Hong Kong. As of October 2020, the company has surpassed the milestone of 1 million accounts on its brokerage platform.

Announcement of becoming a new distributor for OTC equities

On 7^th April 2021, Tiger Brokers had been announced as a new distributor by the OTC Markets Group Inc. for the Real-Time Level 2+ Quotes.

This was a deal-maker step for TIGR stock as now its clients have access to the QTCQX®, QTCB® and Pink® market securities’ real-time depth of book pricing. Leveraging the data on OTC equity securities makes the roster of TIGER online brokerage platform more expansive and allows diverse assistance for trading/decision making for equity investments.

The real-time data and insights makes it more attractive for investors to join the TIGR platform as it provides now an increased options of investment for subscribers and encourages participation in financial market through informed decision making guidance.

April 23, 2021